Phibro Animal Health CORP Form 4 insider transactions

Patrick Rodriguez, VP Finance and Treasurer of Phibro Animal Health Corp, received 1,503 shares of common stock on August 6, 2026.

Glenn David, Chief Financial Officer of Phibro Animal Health Corp, received 3,334 shares of common stock on August 6, 2026.

Larry Lee Miller, Chief Operating Officer of Phibro Animal Health Corp, received 3,522 shares of common stock on August 6, 2026.

Jonathan Bendheim, a Director of Phibro Animal Health Corp, received 2,716 shares of common stock on August 6, 2026.

Judith Weinstein, See Remarks of Phibro Animal Health Corp, received 2,478 shares of common stock on August 6, 2026.

Jack Bendheim and 1 other reported changes in beneficial ownership of Phibro Animal Health Corp common stock on August 6, 2026.

Lisa Ann Escudero, See Remarks of Phibro Animal Health Corp, received 1,547 shares of common stock on August 6, 2026.

Jack Bendheim and 1 other reported changes in beneficial ownership of Phibro Animal Health Corp common stock on August 4, 2026.

Lisa Ann Escudero, See Remarks of Phibro Animal Health Corp, reported a transaction in 265 shares of common stock on August 4, 2026.

Larry Lee Miller, Chief Operating Officer of Phibro Animal Health Corp, reported a transaction in 635 shares of common stock on August 4, 2026.

Judith Weinstein, See Remarks of Phibro Animal Health Corp, reported a transaction in 472 shares of common stock on August 4, 2026.

Glenn David, Chief Financial Officer of Phibro Animal Health Corp, reported a transaction in 840 shares of common stock on August 4, 2026.

Daniel M Bendheim, President and CEO and a Director of Phibro Animal Health Corp, reported a transaction in 486 shares of common stock on August 4, 2026.

Phibro Animal Health Corporation Director E. Thomas Corcoran purchased 10,000 shares of Class A Common Stock.

Phibro Animal Health Corporation CEO Jack Bendheim and BFI Co., LLC sold a total of 18,607 shares of Class A Common Stock via a Rule 10b5-1 trading plan.

Phibro Animal Health Corporation CEO Jack Bendheim and BFI Co., LLC sold a total of 21,117 shares of Class A Common Stock via a pre-arranged 10b5-1 trading plan.

Phibro Animal Health Corporation CEO Jack Bendheim sold 21,520 shares of Class A Common Stock via a pre-arranged 10b5-1 trading plan.

Phibro Animal Health Corporation CEO Jack Bendheim and BFI Co., LLC sold shares of Class A Common Stock under a pre-established Rule 10b5-1 trading plan.

Phibro Animal Health CEO Jack Bendheim and BFI Co., LLC sold a total of 14,080 Class A Common Stock shares in late March 2026 through a pre-arranged 10b5-1 trading plan.

Phibro Animal Health Corp's President and CEO, Jack Bendheim, reported sales of Class A Common Stock totaling 21,180 shares through a pre-arranged Rule 10b5-1 trading plan.

Phibro Animal Health's President and CEO, Jack Bendheim, through BFI Co., LLC, sold 22,880 shares of Class A Common Stock for approximately $1.3 million via a Rule 10b5-1 plan.

An entity controlled by Phibro Animal Health CEO Jack Bendheim converted Class B shares to Class A and subsequently sold a portion of Class A common stock.

Phibro Animal Health CEO Jack Bendheim and BFI Co., LLC sold 21,120 shares of Class A Common Stock through a pre-arranged trading plan.

Phibro Animal Health's President and CEO, Jack Bendheim, along with BFI Co., LLC, sold 14,080 Class A Common Stock shares through a pre-arranged 10b5-1 trading plan.

Phibro Animal Health CEO Jack Bendheim and BFI Co., LLC sold over $727,000 worth of Class A Common Stock through pre-arranged trading plans.

Phibro Animal Health CEO Jack Bendheim and BFI Co., LLC sold 72,198 shares of Class A Common Stock in early February 2026 through a pre-arranged 10b5-1 trading plan.

Phibro Animal Health CFO Glenn David reported the settlement of restricted stock units and subsequent sale of shares for tax obligations.

Phibro Animal Health CEO Jack Bendheim and BFI Co., LLC reported sales of Class A Common Stock and conversion of Class B to Class A shares.

Phibro Animal Health's President and CEO, Jack Bendheim, and BFI Co., LLC, sold a total of 13,465 shares of Class A Common Stock in late January 2026 through a pre-arranged trading plan.

Phibro Animal Health's President and CEO, Jack Bendheim, reported the sale of 1,235 Class A common shares and the conversion of 30,000 Class B shares into Class A common shares.